BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

▤ Summary

BeOne Medicines presented new Phase 3 and real-world data for BRUKINSA in older CLL/SLL patients at EHA 2026. The company highlighted durable progression-free survival and a manageable safety profile in patients aged 80 and older. It also shared evidence from large real-world datasets suggesting BRUKINSA outperforms other BTK inhibitors on survival, treatment persistence, and atrial fibrillation risk. The presentation reinforces BRUKINSA’s positioning as a foundational BTK inhibitor in first-line CLL care.

▦ Linked Companies